A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates

Science Translational Medicine

Volumn 7, Issue 290, 2015, Pages

  Oliveira, Fabiano ^a   Rowton, Edgar ^b   Aslan, Hamide ^a,g   Gomes, Regis ^a,c   Castrovinci, Philip A ^a   Alvarenga, Patricia H ^d   Abdeladhim, Maha ^a   Teixeira, Clarissa ^a,c   Meneses, Claudio ^a   Kleeman, Lindsey T ^a   Guimarães Costa, Anderson B ^a   Rowland, Tobin E ^b   Gilmore, Dana ^a   Doumbia, Seydou ^e   Reed, Steven G ^f   Lawyer, Phillip G ^b   Andersen, John F ^a   Kamhawi, Shaden ^a   Valenzuela, Jesus G ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e UNIVERSITY OF BAMAKO   (Mali)

^f INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^g Selahaddin Eyyubi University   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

LEISHMANIA VACCINE; SALIVA PROTEIN; SAND FLY SALIVARY PROTEIN PDSP15; UNCLASSIFIED DRUG; PROTOZOAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ INTERFERON GAMMA + LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE CARRIER; DRUG EFFICACY; FLY BITE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHLEBOTOMUS DUBOSCQI; PRIMATE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RHESUS MONKEY; SAND FLY; SEQUENCE HOMOLOGY; SKIN LEISHMANIASIS; ANIMAL; IMMUNOLOGY; LEISHMANIASIS, CUTANEOUS; PARASITOLOGY; PSYCHODIDAE;

ANIMALS; HUMANS; INSECT VECTORS; LEISHMANIASIS, CUTANEOUS; PRIMATES; PROTOZOAN VACCINES; PSYCHODIDAE; SALIVARY PROTEINS AND PEPTIDES;

EID: 84930457622     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa3043     Document Type: Article

References (59)

1. J. Schroeder, T. Aebischer, Vaccines for leishmaniasis: From proteome to vaccine candidates. Hum. Vaccin. 7, 10-15 (2011).
2. S. Kamhawi, Y. Belkaid, G. Modi, E. Rowton, D. Sacks, Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 290, 1351-1354 (2000).
3. J. G. Valenzuela, Y. Belkaid, M. K. Garfield, S. Mendez, S. Kamhawi, E. D. Rowton, D. L. Sacks, J. M. Ribeiro, Toward a defined anti-Leishmania vaccine targeting vector antigens: Characterization of a protective salivary protein. J. Exp. Med. 194, 331-342 (2001).
4. R. Gomes, F. Oliveira, C. Teixeira, C. Meneses, D. C. Gilmore, D. E. Elnaiem, S. Kamhawi, J. G. Valenzuela, Immunity to sand fly salivary protein LJM11 modulates host response to vector-transmitted Leishmania conferring ulcer-free protection. J. Invest. Dermatol. 132, 2735-2743 (2012).
5. R. Gomes, C. Teixeira, M. J. Teixeira, F. Oliveira, M. J. Menezes, C. Silva, C. I. de Oliveira, J. C. Miranda, D. E. Elnaiem, S. Kamhawi, J. G. Valenzuela, C. I. Brodskyn, Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc. Natl. Acad. Sci. U.S.A.105, 7845-7850 (2008).
6. F. Oliveira, P. G. Lawyer, S. Kamhawi, J. G. Valenzuela, Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. PLOS Negl. Trop. Dis. 2, e226 (2008).
7. M. E. Rogers, T. Ilg, A. V. Nikolaev, M. A. Ferguson, P. A. Bates, Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature 430, 463-467 (2004).
8. N. C. Peters, N. Kimblin, N. Secundino, S. Kamhawi, P. Lawyer, D. L. Sacks, Vector transmission of Leishmania abrogates vaccine-induced protective immunity. PLOS Pathog. 5, e1000484 (2009).
9. World Health Organization, Leishmaniasis, Fact sheet No 375, 2014; http://www.who.int/mediacentre/factsheets/fs375/en/.
10. P. D. Ready, Biology of phlebotomine sand flies as vectors of disease agents. Annu. Rev. Entomol. 58, 227-250 (2013).
11. R. Reithinger, J. C. Dujardin, H. Louzir, C. Pirmez, B. Alexander, S. Brooker, Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581-596 (2007).
12. L. Holm, P. Rosenström, Dali server: Conservation mapping in 3D. Nucleic Acids Res. 38, W545-W549 (2010).
13. H1-mediated and persists to midlife. J. Invest. Dermatol. 133, 452-459 (2013).
14. F. Oliveira, S. Kamhawi, A. E. Seitz, V. M. Pham, P. M. Guigal, L. Fischer, J. Ward, J. G. Valenzuela, From transcriptome to immunome: Identification of DTH inducing proteins from a Phlebotomus ariasi salivary gland cDNA library. Vaccine 24, 374-390 (2006).
15. R. Gomes, F. Oliveira, The immune response to sand fly salivary proteins and its influence on leishmania immunity. Front. Immunol. 3, 110 (2012).
16. M. Abdeladhim, S. Kamhawi, J. G. Valenzuela, What's behind a sand fly bite? The profound effect of sand fly saliva on host hemostasis, inflammation and immunity. Infect. Genet. Evol. 28, 691-703 (2014).
17. N. Saljoughian, T. Taheri, F. Zahedifard, Y. Taslimi, F. Doustdari, A. Bolhassani, D. Doroud, H. Azizi, K. Heidari, M. Vasei, N. Namvar Asl, B. Papadopoulou, S. Rafati, Development of novel primeboost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLOS Negl. Trop. Dis. 7, e2174 (2013).
18. F. Zahedifard, E. Gholami, T. Taheri, Y. Taslimi, F. Doustdari, N. Seyed, F. Torkashvand, C. Meneses, B. Papadopoulou, S. Kamhawi, J. G. Valenzuela, S. Rafati, Enhanced protective efficacy of non-pathogenic recombinant Leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. PLOS Negl. Trop. Dis. 8, e2751 (2014).
19. M. E. Rogers, O. V. Sizova, M. A. Ferguson, A. V. Nikolaev, P. A. Bates, Synthetic glycovaccine protects against the bite of Leishmania-infected sand flies. J. Infect. Dis. 194, 512-518 (2006).
20. R. Gomes, C. Teixeira, F. Oliveira, P. G. Lawyer, D. E. Elnaiem, C. Meneses, Y. Goto, A. Bhatia, R. F. Howard, S. G. Reed, J. G. Valenzuela, S. Kamhawi, KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. PLOS Negl. Trop. Dis. 6, e1610 (2012).
21. T. Lestinova, M. Vlkova, J. Votypka, P. Volf, I. Rohousova, Phlebotomus papatasi exposure cross-protects mice against Leishmania major co-inoculated with Phlebotomus duboscqi salivary gland homogenate. Acta Trop. 144, 9-18 (2015).
22. M. Abdeladhim, A. M. Ben, S. Marzouki, H. N. Belhadj, T. Boussoffara, H. N. Belhaj, S. A. Ben, H. Louzir, Human cellular immune response to the saliva of Phlebotomus papatasi is mediated by IL-10-producing CD8+ T cells and Th1-polarized CD4+ lymphocytes. PLOS Negl. Trop. Dis. 5, e1345 (2011).
23. S. Marzouki, M. Abdeladhim, C. B. Abdessalem, F. Oliveira, B. Ferjani, D. Gilmore, H. Louzir, J. G. Valenzuela, A. M. Ben, Salivary antigen SP32 is the immunodominant target of the antibody response to Phlebotomus papatasi bites in humans. PLOS Negl. Trop. Dis. 6, e1911 (2012).
24. E. Hajjar, D. Perahia, H. Debat, C. Nespoulous, C. H. Robert, Odorant binding and conformational dynamics in the odorant-binding protein. J. Biol. Chem. 281, 29929-29937 (2006).
25. 2/cysteinyl leukotriene-binding protein from the saliva of a mosquito vector of the malaria parasite. PLOS Biol. 8, e1000547 (2010).
26. N. Collin, R. Gomes, C. Teixeira, L. Cheng, A. Laughinghouse, J. M. Ward, D. E. Elnaiem, L. Fischer, J. G. Valenzuela, S. Kamhawi, Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLOS Pathog. 5, e1000441 (2009).
27. K. Jain, N. K. Jain, Vaccines for visceral leishmaniasis: A review. J. Immunol. Methods, 10.1016/j.jim.2015.03.017 (2015).
28. R. Kumar, C. Engwerda, Vaccines to prevent leishmaniasis. Clin. Transl. Immunol. 3, e13 (2014).
29. V. S. Raman, M. S. Duthie, C. B. Fox, G. Matlashewski, S. G. Reed, Adjuvants for Leishmania vaccines: From models to clinical application. Front. Immunol. 3, 144 (2012).
30. N. Kimblin, N. Peters, A. Debrabant, N. Secundino, J. Egen, P. Lawyer, M. P. Fay, S. Kamhawi, D. Sacks, Quantification of the infectious dose of Leishmania major transmitted to the skin by single sand flies. Proc. Natl. Acad. Sci. U.S.A. 105, 10125-10130 (2008).
31. C. Maia, V. Seblova, J. Sadlova, J. Votypka, P. Volf, Experimental transmission of Leishmania infantum by two major vectors: A comparison between a viscerotropic and a dermotropic strain. PLOS Negl. Trop. Dis. 5, e1181 (2011).
32. N. F. Secundino, V. C. de Freitas, C. C. Monteiro, A. C. Pires, B. A. David, P. F. Pimenta, The transmission of Leishmania infantum chagasi by the bite of the Lutzomyia longipalpis to two different vertebrates. Parasit. Vectors 5, 20 (2012).
33. R. J. Probst, B. T. Wellde, P. G. Lawyer, J. S. Stiteler, E. D. Rowton, Rhesus monkey model for Leishmania major transmitted by Phlebotomus papatasi sandfly bites. Med. Vet. Entomol. 15, 12-21 (2001).
34. V. Vinhas, B. B. Andrade, F. Paes, A. Bomura, J. Clarencio, J. C. Miranda, A. Báfica, A. Barral, M. Barral-Netto, Human anti-saliva immune response following experimental exposure to the visceral leishmaniasis vector, Lutzomyia longipalpis. Eur. J. Immunol. 37, 3111-3121 (2007).
35. J. M. Anderson, S. Samake, G. Jaramillo-Gutierrez, I. Sissoko, C. A. Coulibaly, B. Traoré, C. Soucko, B. Guindo, D. Diarra, M. P. Fay, P. G. Lawyer, S. Doumbia, J. G. Valenzuela, S. Kamhawi, Seasonality and prevalence of Leishmania major infection in Phlebotomus duboscqi Neveu-Lemaire from two neighboring villages in central Mali. PLOS Negl. Trop. Dis. 5, e1139 (2011).
36. H1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843-850 (2007).
37. + T cell responses. J. Exp. Med. 204, 1405-1416 (2007).
38. S.-H. Park, E.-C. Shin, S. Capone, L. Caggiari, V. De Re, A. Nicosia, A. Folgori, B. Rehermann, Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 143, 1048-1060.e4 (2012).
39. E. K. Forbes, C. Sander, E. O. Ronan, H. McShane, A. V. Hill, P. C. Beverley, E. Z. Tchilian, Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181, 4955-4964 (2008).
40. S. C. Derrick, I. M. Yabe, A. Yang, S. L. Morris, Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29, 2902-2909 (2011).
41. + T cells. Blood 107, 4781-4789 (2006).
42. R. A. Seder, P. A. Darrah, M. Roederer, T-cell quality in memory and protection: Implications for vaccine design. Nat. Rev. Immunol. 8, 247-258 (2008).
43. W. R. Faber, L. Oskam, T. van Gool, N. C. Kroon, K. J. Knegt-Junk, H. Hofwegen, A. C. van der Wal, P. A. Kager, Value of diagnostic techniques for cutaneous leishmaniasis. J. Am. Acad. Dermatol. 49, 70-74 (2003).
44. A. Sassi, H. Louzir, S. A. Ben, M. Mokni, O. A. Ben, K. Dellagi, Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin. Exp. Immunol. 116, 127-132 (1999).
45. R. Alvarado, C. Enk, K. Jaber, L. Schnur, S. Frankenburg, Delayed-type hypersensitivity and lymphocyte proliferation in response to Leishmania major infection in a group of children in Jericho. Trans. R. Soc. Trop. Med. Hyg. 83, 189-192 (1989).
46. E. A. Khalil, H. AMEl, E. E. Zijlstra, M. M. Mukhtar, H. W. Ghalib, B. Musa, M. E. Ibrahim, A. A. Kamil, M. Elsheikh, A. Babiker, F. Modabber, Autoclaved Leishmania majorvaccinefor prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356, 1565-1569 (2000).
47. M. Castés, J. Blackwell, D. Trujillo, S. Formica, M. Cabrera, G. Zorrilla, A. Rodas, P. L. Castellanos, J. Convit, Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-γ production. Vaccine 12, 1041-1051 (1994).
48. W. Mayrink, C. A. da Costa, P. A. Magalhães, M. N. Melo, M. Dias, A. O. Lima, M. S. Michalick, P. Williams, A field trial of a vaccine against American dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 73, 385-387 (1979).
49. S. A. Ben, H. Louzir, S. Chlif, M. Mokni, A. Zaatour, M. Raouene, R. B. Ismail, K. Dellagi, The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis. J. Infect. Dis. 192, 1981-1987 (2005).
50. O. Bacellar, D. Faria, M. Nascimento, T. M. Cardoso, K. J. Gollob, W. O. Dutra, P. Scott, E. M. Carvalho, Interleukin 17 production among patients with American cutaneous leishmaniasis. J. Infect. Dis. 200, 75-78 (2009).
51. S. Brosch, K. Dietze-Schwonberg, S. Lopez Kostka, B. Lorenz, S. Haak, B. Becher, E. von Stebut, Disease control in cutaneous leishmaniasis is independent of IL-22. J. Invest. Dermatol. 135, 308-311 (2015).
52. N. S. Geraci, R. M. Mukbel, M. T. Kemp, M. N. Wadsworth, E. Lesho, G. M. Stayback, M. M. Champion, M. A. Bernard, M. Abo-Shehada, I. V. Coutinho-Abreu, M. Ramalho-Ortigão, H. A. Hanafi, E. Y. Fawaz, S. S. El-Hossary, G. Wortmann, D. F. Hoel, M. A. McDowell, Profiling of human acquired immunity against the salivary proteins of Phlebotomus papatasi reveals clusters of differential immunoreactivity. Am. J. Trop. Med. Hyg. 90, 923-938 (2014).
53. S. Nakae, Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, Y. Iwakura, Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17, 375-387 (2002).
54. M. B. Teunissen, C. W. Koomen, R. de Waal Malefyt, E. A. Wierenga, J. D. Bos, Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111, 645-649 (1998).
55. P. Probst, E. Stromberg, H. W. Ghalib, M. Mozel, R. Badaro, S. G. Reed, J. R. Webb, Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J. Immunol. 166, 498-505 (2001).
56. P. H. Alvarenga, X. Xu, F. Oliveira, A. C. Chagas, C. R. Nascimento, I. M. Francischetti, M. A. Juliano, L. Juliano, J. Scharfstein, J. G. Valenzuela, J. M. Ribeiro, J. F. Andersen, Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate. Arterioscler. Thromb. Vasc. Biol. 33, 2759-2770 (2013).
57. A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
58. J. E. Sokal, Editorial: Measurement of delayed skin-test responses. N. Engl. J. Med. 293, 501-502 (1975).
59. L. Nicolas, E. Prina, T. Lang, G. Milon, Real-time PCR for detection and quantitation of Leishmania in mouse tissues. J. Clin. Microbiol. 40, 1666-1669 (2002).